201 related articles for article (PubMed ID: 18520048)
1. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.
Uchiyama Y; Yorozu K; Hashizume M; Moriya Y; Mihara M
Biol Pharm Bull; 2008 Jun; 31(6):1159-63. PubMed ID: 18520048
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
Hashizume M; Uchiyama Y; Horai N; Tomosugi N; Mihara M
Rheumatol Int; 2010 May; 30(7):917-23. PubMed ID: 19639319
[TBL] [Abstract][Full Text] [Related]
3. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model.
Kato A; Matsuo S; Takai H; Uchiyama Y; Mihara M; Suzuki M
Exp Mol Pathol; 2008 Jun; 84(3):262-70. PubMed ID: 18511040
[TBL] [Abstract][Full Text] [Related]
4. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys.
Mihara M; Kotoh M; Nishimoto N; Oda Y; Kumagai E; Takagi N; Tsunemi K; Ohsugi Y; Kishimoto T; Yoshizaki K; Takeda Y
Clin Immunol; 2001 Mar; 98(3):319-26. PubMed ID: 11237555
[TBL] [Abstract][Full Text] [Related]
5. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production.
Uchiyama Y; Yoshida H; Koike N; Hayakawa N; Sugita A; Nishimura T; Mihara M
Int Immunopharmacol; 2008 Nov; 8(11):1595-601. PubMed ID: 18664393
[TBL] [Abstract][Full Text] [Related]
7. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.
Takagi N; Mihara M; Moriya Y; Nishimoto N; Yoshizaki K; Kishimoto T; Takeda Y; Ohsugi Y
Arthritis Rheum; 1998 Dec; 41(12):2117-21. PubMed ID: 9870868
[TBL] [Abstract][Full Text] [Related]
8. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis.
Abdel-Maged AE; Gad AM; Abdel-Aziz AK; Aboulwafa MM; Azab SS
Toxicol Appl Pharmacol; 2018 Oct; 356():65-75. PubMed ID: 30025850
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of the extract of Phellodendron amurense ruprecht root on collagen-induced arthritis in mice.
Jung HW; Kim KH; Park YK
Chin J Integr Med; 2017 Oct; 23(10):755-762. PubMed ID: 27460490
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
14. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
15. Torilin ameliorates type II collagen-induced arthritis in mouse model of rheumatoid arthritis.
Endale M; Lee WM; Kwak YS; Kim NM; Kim BK; Kim SH; Cho J; Kim S; Park SC; Yun BS; Ko D; Rhee M
Int Immunopharmacol; 2013 Jun; 16(2):232-42. PubMed ID: 23623942
[TBL] [Abstract][Full Text] [Related]
16. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
Gibiansky L; Frey N
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
[TBL] [Abstract][Full Text] [Related]
17. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
Zhang X; Georgy A; Rowell L
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):443-55. PubMed ID: 23547848
[TBL] [Abstract][Full Text] [Related]
20. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
